Showing results (41-50 of 66) with videos related to
Sort By:
Pageof 7
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|October 1, 1994
Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumorsJ A Sparano, R I Fisher, G R Weiss, et al.Journal of Cancer Research and Clinical Oncology|April 6, 2002
Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working GroupK Margolin, B Atkins, A Thompson, et al.The Cancer Journal From Scientific American|May 1, 1997
Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group StudyJ P Dutcher, R I Fisher, G Weiss, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993M B Atkins, M T Lotze, J P Dutcher, et al.Gynecologic Oncology|June 1, 2000
Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-upR J Morgan, P Braly, L Leong, et al.British Journal of Cancer|August 15, 2002
Predictors of long-term outcome following high-dose chemotherapy in high-risk primary breast cancerG Somlo, J F Simpson, P Frankel, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2001
Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trialsL E Flaherty, M Atkins, J Sosman, et al.Cancer Chemotherapy and Pharmacology|May 11, 2001
Continuous infusion prochlorperazine: pharmacokinetics, antiemetic efficacy, and feasibility of high-dose therapyR J Morgan, T Synold, B I Carr, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2001
Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignanciesM L Tetef, T W Synold, W Chow, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1997
High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survivalG Somlo, J H Doroshow, S J Forman, et al.Pageof 7